Summary

Molecular Neurooncology Laboratory

The aim of preclinical research at the Dr. Senckenberg Institute of Neurooncology is to elucidate the molecular mechanisms of treatment resistance in models of malignant gliomas and to develop novel treatment strategies.

Specific interests are the role of the tumor microenvironment in the development of treatment resistance and the analysis of stress pathways.

Another focus of interest is the development of immunotherapy for malignant gliomas with genetically modified natural killer (NK) cells in collaboration with the Georg-Speyer-Haus and the Blutspendedienst Hessen.

Clinical Trial Unit

Investigator-initiated trials currently in preparation include the CAR2BRAIN trial with application of genetically modified natural killer (NK) cells to patients with glioblastoma recurrence and the XVir trial with application of recombination-competent oncolytic virus to patients with glioblastoma recurrence.

The ERGO trials focus on analysis and application of nutritional therapies targeting metabolism. Imaging trials investigating properties of mutant IDH and other  molecules  by means advanced MR techniques are pursued in collaboration with the Institute of Neuroradiology and the Brain Imaging Center.